TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Separately, Noble Financial restated a “buy” rating and set a $17.50 target price on shares of TherapeuticsMD in a report on Monday, July 11th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.71 on Wednesday. The stock’s market cap is $1.32 billion. TherapeuticsMD has a 12 month low of $5.18 and a 12 month high of $11.26. The firm has a 50-day moving average price of $6.73 and a 200-day moving average price of $7.68.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The company had revenue of $4.40 million for the quarter, compared to analyst estimates of $5.63 million. The company’s quarterly revenue was down 8.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) EPS. Equities analysts expect that TherapeuticsMD will post ($0.43) EPS for the current fiscal year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.